Log In
Print
BCIQ
Print
Print this Print this
 

Ultibro Breezhaler, Ulunar Breezhaler, indacaterol/glycopyrronium bromide (QVA149)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionFixed-dose combination of glycopyrronium bromide (NVA237), an inhaled long-acting muscarinic receptor antagonist (LAMA), and indacaterol, a long-acting adrenergic receptor beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2) ; Muscarinic receptor
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist; Muscarinic receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsMaintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD); Treat chronic obstructive pulmonary disease (COPD)
Regulatory Designation

EU - Standard Review (Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD));
Japan - Standard Review (Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD))

Partner

Sosei Group Corp.; Vectura Group plc


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today